LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera DAEJEON, South Korea--(BUSINESS WIRE)--LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter “LegoChemBio”) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by [...]

Consortium of industrial and academic partners led by Elthera receives Eurostars grant SCHLIEREN, SCHWEIZ, November 10, 2020 /EINPresswire.com/ -- Elthera AG, iCellate Medical AB, Targos GmbH and Prof. Dr. Susanne Sebens at the Institute of Experimental Cancer Research (IET) at the University of Kiel are proud to announce that [...]

Elthera Awarded 2.5 M € Grant From Horizon 2020 Program ZURICH, June 17, 2019 /PRNewswire/ -- Elthera is pleased to announce that it has been awarded 2.5 M € through the Horizon 2020 programme. Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative, [...]

Elthera Announces Positive Preclinical Proof of Concept (POC) Studies and Start of New Financing SCHLIEREN, Switzerland, March 19, 2018 ---Elthera is pleased to announce that it has demonstrated efficacy of its proprietary antibodies in tumor bearing animals. Anne Schmidt, Elthera CEO said, “We are very encouraged by these results demonstrating [...]